Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1307)	7/22/2005 1:16:45 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IDEV Is trading above its July Hs to continue on its nearterm uptrend that started on July 15 from the 2.80 level. The stock needs to close above its June 17 H of 3,34 in order to get off from its intermediate tem downtrend coming fro the May 31 H at 3.78 But IDEV seems to be forming a good base and it may get to test the February 4 H at 5.25 if it continues to report a good increase in revenues as it has been doing in the last 4 Qs.<g> The loss in the last Q was also cut by 3 cents.<g> Back in February some insiders bought at $4.05 and in March there were several buying, albeit at lower levels.<g> IDEV revenues on the 2ndQ were up 955% to $9.3M from $0.88M in 2004 On July 14 it announced that it was starting a PII of pagoclone in patients with persistent developmental stuttering. And on June 13 the court upheld the patent that IDEV licensed to LLY for Sarafem, rejecting a challenge from TEVA Also on June 15 it announced good results of its PII of Sanctura for over acatice bladder and it has PRO 2000 for HIV and other sexually transmitted pathogens,aminocandin for fungal infections, and IP 751 for interstitial cystitis. The stock has been up almost 6% today bigcharts.marketwatch.com Bernard